Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ).
Jacobio Pharmaceuticals Group Co., Ltd. has announced the appointment of Dr. Andrea Wang-Gillam as Co-Chief Executive Officer, effective November 12, 2025. This strategic move aims to enhance the company’s global strategic deployment and operational efficiency, particularly in overseas markets. Dr. Wang-Gillam brings extensive experience in oncology and international pharmaceutical markets, which is expected to strengthen Jacobio’s international strategy and create greater value for its shareholders.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a company in the pharmaceutical industry, focusing on the development and commercialization of anti-tumor drugs. The company has established teams in the United States for clinical trial management and business development, and it conducts multicenter clinical trials and collaborations in Europe and the United States as part of its international strategy.
Average Trading Volume: 8,484,676
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.43B
For an in-depth examination of 1167 stock, go to TipRanks’ Overview page.